Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CYP2C19 genotype and the PPIs--focus on rabeprazole.

P W Y Lim1, K L Goh, B C Y Wong

  • 1Eisai Co., Ltd, c/o Eisai Asia Regional Services Pte Ltd, Singapore. p-lim@hhc.eisai.co.jp

Journal of Gastroenterology and Hepatology
|December 20, 2005
PubMed
Summary

Rabeprazole, a proton pump inhibitor (PPI), shows minimal dependence on CYP4502C19 metabolism. This makes it less affected by genetic variations, ensuring consistent acid reduction for acid-related disorders.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transcriptional profiling of male mouse muscle across aging stages: a gene ontology analysis of the muscle matreotype.

BMC genomics·2026
Same author

Age-dependent mechanical properties of tail tendons in wild-type and mimecan gene-knockout mice - A preliminary study.

Journal of the mechanical behavior of biomedical materials·2023
Same author

Post-process optimization of 3D printed poly(lactic-co-glycolic acid) dental implant scaffold for enhanced structure and mechanical properties: effects of sonication duration and power.

Journal of materials science. Materials in medicine·2021
Same author

Dataset on open/blind hole-hole interaction in barely visible impact damaged composite laminates.

Data in brief·2020
Same author

Modified Unipolar Hemiarthroplasty for the Treatment of Metastatic Lesions of Proximal Femur with Pathological Fractures: Case Series of Six Patients.

Malaysian orthopaedic journal·2020
Same author

Editor's note.

JGH open : an open access journal of gastroenterology and hepatology·2020

Area of Science:

  • Pharmacology
  • Gastroenterology

Background:

  • Proton pump inhibitors (PPIs) are mainstays in treating acid-related disorders.
  • CYP4502C19 genetic polymorphism influences the metabolism and efficacy of many PPIs.
  • Understanding inter-individual variability in PPI response is crucial for optimizing therapy.

Purpose of the Study:

  • To evaluate the metabolic profile of rabeprazole in relation to CYP4502C19.
  • To determine the impact of CYP4502C19 genetic polymorphism on rabeprazole's efficacy.
  • To highlight rabeprazole's potential advantages in managing acid-related conditions.

Main Methods:

  • Review of existing pharmacokinetic and pharmacogenetic studies on rabeprazole.
  • Comparative analysis of rabeprazole's metabolic pathways against other PPIs.

Related Experiment Videos

  • Assessment of clinical data linking CYP4502C19 status to rabeprazole's acid-suppressive effects.

    • Main Results:

    • Rabeprazole exhibits the lowest hepatic metabolism dependency on the CYP4502C19 system among all PPIs.
    • Consequently, rabeprazole is least affected by CYP4502C19 genetic polymorphism.
    • This metabolic characteristic contributes to rabeprazole's rapid onset of action.

    Conclusions:

    • Rabeprazole's unique metabolic profile offers predictable and consistent gastric acid inhibition.
    • It presents a favorable option for patients with varying CYP4502C19 genotypes.
    • This may lead to improved treatment outcomes for acid-related disorders.